Pembrolizumab
Monoclonal antibody targets FAP, FGFR4, PDCD1, TREM2 via inhibition / depletion
Regulatory milestones approvals, filings & regulatory actions · 83 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (81) | US (FDA) | KEYTRUDA | — | 2015-10-02 – 2026-07-10 | fda.gov ↗ |
| Approved | EU (EMA) | Keytruda | — | 2015-07-17 | europa.eu ↗ |
| Approved | US (FDA) | KEYTRUDA | — | 2014-09-04 | fda.gov ↗ |
Trials 2,143 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 042 trials | ||||||
| Phase 0 | NCT07689643 | Apr 2026 → Sep 2027 expected | non-small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 0 | NCT06637306 | Mar 2025 → Mar 2027 expected | triple-negative breast carcinoma | Rima Patel | Recruiting | No outcome recorded |
| Phase 0 | NCT06308913 | Sep 2024 → Oct 2026 expected | head and neck squamous cell carcinoma | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT05916248 | Dec 2023 → Jun 2026 overdue | neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05553782 | Nov 2023 → Apr 2029 expected | head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05733715 | May 2023 → Jun 2026 overdue | renal cell carcinoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT05916261 | Apr 2023 → Nov 2026 expected | pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05493566 | Nov 2022 → Jan 2027 expected | non-small cell lung carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT05488366 | Aug 2022 → Jun 2025 overdue | soft tissue sarcoma | University of California, Irvine | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06413095 | Jun 2022 → Jun 2023 | head and neck squamous cell carcinoma, soft tissue sarcoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT05204290 | Mar → Oct 2022 | cancer, epidural spinal canal neoplasm | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 0 | NCT05041153 | Feb 2022 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04777708 | Oct 2021 → Mar 2023 | hepatocellular carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT04677361 | Oct 2021 → Oct 2023 | non-small cell lung carcinoma, small cell lung carcinoma | Fox Chase Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04581382 | Dec 2020 → Oct 2024 | melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT04265872 | Oct 2020 → Dec 2026 expected | breast cancer | Baylor Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT04220892 | Jul 2020 | high grade astrocytic tumor | Jose Carrillo | Withdrawn | No outcome recorded |
| Phase 0 | NCT02982902 | May 2020 → Aug 2027 expected | cytomegalovirus infection, disease related to hematopoietic stem cell transplant | Mari Dallas | Recruiting | No outcome recorded |
| Phase 0 | NCT04188951 | Oct 2019 → Jun 2023 | head and neck neoplasm | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT04134325 | Sep 2019 → Apr 2025 overdue | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03694834 | Mar 2019 → Oct 2023 | endometrial cancer | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT03832569 | Feb 2019 → Feb 2027 expected | cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03574220 | Feb 2019 → Mar 2020 | non-small cell lung carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT03815084 | Feb 2019 → Feb 2020 | neoplasm | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT03815630 | Feb 2019 → Feb 2020 | neoplasm | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT03599453 | Jan 2019 → Sep 2020 | triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 0 | NCT03153410 | Sep 2018 → Mar 2022 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 0 | NCT03514121 | Mar 2018 → Apr 2021 | breast cancer, endometrial cancer, ovarian cancer | Five Prime Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 0 | NCT03445858 | Feb 2018 → Nov 2023 | adult lymphoma, pediatric lymphoma, refractory malignant neoplasm | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 0 | NCT03395847 | Feb 2018 → Jan 2023 | esophageal adenocarcinoma, gastric carcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03197389 | Jan 2018 → Mar 2020 | triple-negative breast carcinoma | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 0 | NCT03276832 | Dec 2017 → Oct 2019 | cutaneous melanoma, metastatic melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT03291353 | Oct 2017 → Aug 2019 | acute myeloid leukemia | Michael Boyiadzis | Withdrawn | No outcome recorded |
| Phase 0 | NCT03224871 | Aug 2017 → Jan 2020 | non-small cell lung carcinoma | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT03099564 | Mar 2017 → May 2021 | hepatocellular carcinoma | Hoosier Cancer Research Network | Unknown | No outcome recorded |
| Phase 0 | NCT02981914 | Mar 2017 → Oct 2020 | B-cell non-Hodgkin lymphoma, acute myeloid leukemia, classic Hodgkin lymphoma, myelodysplastic syndrome | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT02872025 | Dec 2016 → Mar 2026 overdue | ductal breast carcinoma in situ | Laura Esserman | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02603887 | Jul 2016 → Dec 2017 overdue | smoldering plasma cell myeloma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02728830 | Jun 2016 → Jan 2019 | endometrial cancer, fallopian tube cancer, ovarian carcinoma, peritoneum cancer | AA Secord | Completed | No outcome recorded |
| Phase 1427 trials | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07388550 | Jul 2026 → Jan 2028 expected | post-COVID-19 disorder | National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06724042 | Jun 2026 → Jun 2029 expected | metastatic neoplasm, neoplasm | InSilico Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07687875 | Jun 2026 → Dec 2028 expected | rectal cancer | Henry Smith | Recruiting | No outcome recorded |
| Phase 1 | NCT07199413 | Jun 2026 → Apr 2029 | malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT07385846 | Jun 2026 → Jun 2028 expected | glioblastoma | Jennifer Leddon | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07652242 | Jun 2026 → Feb 2028 expected | triple-negative breast carcinoma | Immunomic Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07610941 | Apr 2026 → Dec 2029 expected | cancer | Mestag Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT07501650 | Mar 2026 → Mar 2027 expected | head and neck cancer, small cell carcinoma | Thomas Jefferson University | Recruiting | No outcome recorded |
| Phase 1 | NCT07217496 | Feb 2026 → May 2027 | urothelial carcinoma | Vadim S Koshkin | Withdrawn | No outcome recorded |
| Show all 427 trials opens the full record — a long page | ||||||
| Phase 1/2352 trials | ||||||
| Phase 1/2 | NCT07667335 | Dec 2026 → Jul 2029 expected | infiltrating urothelial carcinoma, urinary bladder carcinoma, urothelial carcinoma | Fred Hutchinson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07552558 | Jun 2026 → Aug 2028 expected | head and neck squamous cell carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07302347 | Jun 2026 → Mar 2029 expected | cutaneous neuroendocrine carcinoma, lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07639450 | Jun 2026 → Aug 2028 expected | cancer | Hefei Xinzhu Biological Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07591597 | May 2026 → Jul 2027 expected | colorectal cancer | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05806385 | Mar 2026 → Jan 2027 expected | triple-negative breast carcinoma | Texas Tech University Health Sciences Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07327229 | Feb 2026 → Sep 2027 expected | gastroesophageal adenocarcinoma | Antengene Biologics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07410676 | Feb 2026 → Dec 2028 expected | breast cancer, colorectal cancer, cutaneous melanoma, esophageal cancer +9 | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06405230 | Dec 2025 → Aug 2028 expected | non-small cell lung carcinoma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07282509 | Dec 2025 → Jun 2028 expected | hepatocellular carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Show all 352 trials opens the full record — a long page | ||||||
| Phase 21,066 trials | ||||||
| Phase 2 | NCT07037004 | Jan 2027 → Oct 2028 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07603856 | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07691476 | Oct 2026 → Oct 2028 expected | nonpapillary renal cell carcinoma | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07643519 | Oct 2026 → Feb 2029 expected | urothelial carcinoma | University of Florida | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07680088 | Sep 2026 → Sep 2028 expected | anal squamous cell carcinoma | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07663747 | Sep 2026 → Apr 2031 expected | urinary bladder cancer | The Netherlands Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07594015 | Sep 2026 → Sep 2031 expected | endometrial cancer | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT06863402 | Aug 2026 → Jun 2029 expected | B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07634094 | Aug 2026 → Aug 2028 expected | ovarian cancer | Kalinski, Pawel, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07460206 | Aug 2026 → Aug 2031 expected | clear cell renal carcinoma | Italian Oncology Group for Clinical Research | Not yet recruiting | No outcome recorded |
| Show all 1,066 trials opens the full record — a long page | ||||||
| Phase 2/324 trials | ||||||
| Phase 2/3 | NCT07572123 | Dec 2026 → Mar 2029 expected | classic Hodgkin lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07000253 | Apr 2026 → Jun 2031 expected | carcinoma of esophagus, gastric adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07332533 | Dec 2025 → Jun 2032 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06624644 | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06697301 | May 2025 → Dec 2035 expected | melanoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06923475 | May 2025 → Nov 2028 expected | distal biliary tract carcinoma, hilar cholangiocarcinoma | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06493552 | Mar 2025 → Sep 2029 expected | urinary bladder carcinoma, urothelial carcinoma | Vasgene Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06513884 | Dec 2024 → Nov 2029 | oropharynx squamous cell carcinoma | Hookipa Biotech GmbH | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT06295731 | May 2024 → May 2029 expected | head and neck squamous cell carcinoma | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06295809 | Apr 2024 → Mar 2026 | skin neoplasm, squamous cell carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2/3 | NCT06236438 | Apr 2024 → Oct 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06276504 | Apr 2024 → Apr 2028 expected | progressive multifocal leukoencephalopathy | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06907602 | Jan 2024 → Dec 2026 expected | esophageal squamous cell carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05595447 | Oct 2022 → Oct 2025 overdue | Hodgkins lymphoma | Hospital Regional de Alta Especialidad del Bajio | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05255302 | May 2022 → May 2025 overdue | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05322187 | Apr 2022 → Sep 2023 | childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05096663 | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04969861 | Mar → Apr 2022 | head and neck cancer | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 2/3 | NCT04534205 | Jan 2021 → Apr 2029 expected | head and neck squamous cell carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04750083 | Sep 2020 → Sep 2022 | non-small cell lung carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04093167 | May 2020 → Dec 2026 expected | lung cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04322617 | Mar 2020 → Mar 2028 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03755739 | Nov 2018 → Nov 2033 expected | breast cancer, cervical cancer, colorectal cancer, head and neck cancer +6 | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01905657 | Aug 2013 → Sep 2015 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3193 trials | ||||||
| Phase 3 | NCT07689240 | Feb 2027 → Jan 2032 expected | nonpapillary renal cell carcinoma, renal cell adenocarcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07178730 | Jun 2026 → Mar 2033 expected | triple-negative breast carcinoma | West German Study Group | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07673887 | Jun 2026 → Feb 2031 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Astellas Pharma Global Development, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07660094 | Jun 2026 → Oct 2031 expected | non-small cell lung carcinoma | Candel Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07566156 | May 2026 → Mar 2030 expected | urinary bladder neoplasm, urothelial carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07509099 | Apr 2026 → Sep 2030 expected | head and neck squamous cell carcinoma | Ji Dongmei | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07486687 | Apr 2026 → Apr 2032 expected | female breast carcinoma, triple-negative breast carcinoma | The Netherlands Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07198074 | Jan 2026 → Jul 2028 expected | endometrial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT07216703 | Jan 2026 → Oct 2031 expected | cervical cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06749925 | Jan 2026 → Jan 2028 expected | glioblastoma | University of Sao Paulo General Hospital | Not yet recruiting | No outcome recorded |
| Show all 193 trials opens the full record — a long page | ||||||
| Phase 412 trials | ||||||
| Phase 4 | NCT07574047 | Sep 2026 → Jun 2030 expected | melanoma | Swiss Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07645625 | May 2026 → May 2030 expected | cervical cancer | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 4 | NCT07010393 | Jul 2025 → Dec 2027 expected | thyroid tumor | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06764095 | Jan 2025 → Dec 2034 expected | bladder transitional cell carcinoma, renal pelvis/ureter urothelial carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06550453 | Sep 2024 → Jan 2025 overdue | colorectal carcinoma | yangjianjun | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT04489888 | Oct 2020 → Feb 2023 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT04554524 | Aug 2020 → Jul 2024 | combined thymoma | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03891979 | Jun 2019 → Jun 2020 | malignant pancreatic neoplasm | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT03715205 | Jan 2019 → Aug 2024 | melanoma, non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT03134456 | May 2018 → Jul 2019 | non-small cell lung carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02690935 | Mar 2016 → Apr 2017 | seasonal allergic rhinitis | Labo'Life | Completed | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07343596 | Apr 2026 → Dec 2027 expected | oral cavity cancer | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| — | NCT07067450 | Jul 2025 → Dec 2026 expected | esophageal squamous cell carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| — | NCT06643910 | Oct 2024 → Aug 2026 overdue | non-small cell lung carcinoma | BioSyngen Pte Ltd | Not yet recruiting | No outcome recorded |
| — | NCT06549855 | Oct 2024 → Jul 2029 expected | endometrial cancer, endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06341478 | Mar 2024 → Mar 2026 overdue | urinary bladder cancer | IRCCS San Raffaele | Recruiting | No outcome recorded |
| — | NCT06676293 | Aug 2023 → Apr 2024 | nasopharyngeal carcinoma | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT05352165 | Jan 2023 → Dec 2024 | — | Shanghai Minimally Invasive Surgery Center | Unknown | No outcome recorded |
| — | NCT05339581 | May 2022 → Dec 2023 | hepatocellular carcinoma, portal vein thrombosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT07428252 | Mar 2022 → Mar 2024 overdue | metastatic melanoma | Institute of Oncology Ljubljana | Active not recruiting | No outcome recorded |
| — | NCT07422779 | Mar 2022 → Mar 2027 expected | metastatic melanoma, skin cancer | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| — | NCT05368207 | Dec 2021 → Oct 2025 | hypercalcemic type ovarian small cell carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| — | NCT05047094 | Nov 2021 → Dec 2026 expected | head and neck squamous cell carcinoma, skin cancer | Alpha Tau Medical LTD. | Recruiting | No outcome recorded |
| — | NCT04801966 | Sep 2021 → Dec 2022 | cancer | Peter MacCallum Cancer Centre, Australia | Terminated | No outcome recorded |
| — | NCT05902260 | Jul 2021 → Apr 2024 | non-small cell lung carcinoma | Joachim Aerts, MD PhD | Completed | No outcome recorded |
| — | NCT04793815 | May 2021 → Jun 2023 | non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| — | NCT04393883 | Apr 2021 → Jul 2022 | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05745233 | Jan 2021 → Dec 2026 expected | peritoneal neoplasm | China Medical University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT04425226 | Aug 2020 → Dec 2022 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03769129 | Nov 2018 → Nov 2026 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| — | NCT03035890 | Jan 2017 → Jun 2022 | non-small cell lung carcinoma | West Virginia University | Completed | No outcome recorded |
| — | NCT02760225 | Oct 2016 → Mar 2019 | melanoma, non-small cell lung carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
| — | NCT02658279 | Jan 2016 → Jan 2027 expected | malignant glioma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| — | NCT02489357 | Dec 2015 → Nov 2017 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| — | NCT02194738 | Sep 2014 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT03311542 | — | brain glioma, cutaneous melanoma, glioblastoma | Center Trials & Treatment | No longer available | No outcome recorded |
| — | NCT04135092 | — | — | National Institutes of Health Clinical Center (CC) | No longer available | No outcome recorded |
| — | NCT02083484 | — | melanoma | Merck Sharp & Dohme LLC | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 481 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06212388 Comparator | Jan 2024 → Oct 2027 expected | melanoma | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05589961 Background | Oct 2022 → Jul 2024 | glioblastoma | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT05358938 Background | Jun 2022 → Oct 2024 overdue | cutaneous melanoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03371992 Background | Mar 2018 → Dec 2020 | non-small cell lung carcinoma | Nilogen Oncosystems | Unknown | No outcome recorded |
| Phase 1120 trials | ||||||
| Phase 1 | NCT04266730 Background | May → Jun 2027 | head and neck squamous cell carcinoma, non-small cell squamous lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Suspended | No outcome recorded |
| Phase 1 | NCT07619599 Background | Sep 2026 → Dec 2028 expected | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300475 Background | Aug 2026 → May 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07581509 Comparator | Aug 2026 → Dec 2027 expected | — | Biocon Biologics UK Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07475572 Comparator | Jun 2026 → Oct 2027 expected | melanoma | Alvotech Swiss AG | Not yet recruiting | No outcome recorded |
| Show all 120 trials opens the full record — a long page | ||||||
| Phase 1/293 trials | ||||||
| Phase 1/2 | NCT07662720 Background | Jul 2026 → Aug 2027 expected | head and neck squamous cell carcinoma | Glycyx Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07632235 Comparator | Jul 2026 → Dec 2029 expected | intrahepatic cholangiocarcinoma | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07644039 Background | May 2026 → Apr 2029 expected | cancer | PharmaMar | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07428148 Background | May 2026 → May 2031 expected | oropharynx squamous cell carcinoma | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07469774 Background | Mar 2026 → Dec 2027 expected | — | Biocity Biopharmaceutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06400160 Background | Mar 2026 → Mar 2027 expected | colorectal cancer, hepatocellular carcinoma, non-small cell lung carcinoma, prostate cancer | Twinpig Biolab, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07232602 Background | Feb 2026 → Jul 2031 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07287995 Background | Feb 2026 → Jun 2029 expected | — | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07287917 Background | Jan 2026 → Feb 2028 expected | cutaneous melanoma, hormone receptor-positive breast cancer | Aminex Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07262619 Background | Jan 2026 → Mar 2029 expected | colorectal cancer, endometrial cancer, gastroesophageal cancer | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07255664 Background | Nov 2025 → Apr 2027 expected | colorectal cancer, prostate cancer | CuraCell TX AB | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07213934 Background | Oct 2025 → Dec 2030 expected | head and neck squamous cell carcinoma | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06361810 Background | Oct 2025 → Jan 2031 | clear cell renal carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07111520 Comparator | Sep 2025 → Jan 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07040436 Background | Sep 2025 → Sep 2027 expected | melanoma | Oncodesign Precision Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07136545 Background | Aug 2025 → Dec 2026 expected | head and neck squamous cell carcinoma | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07158918 Background | Aug 2025 → Dec 2027 expected | cancer | ABL Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06939036 Background | Jul → Dec 2025 | cutaneous neuroendocrine carcinoma, small cell lung carcinoma | Ariceum Therapeutics GmbH | Terminated | No outcome recorded |
| Phase 1/2 | NCT07020221 Background | Jun 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06579196 Background | May 2025 → Mar 2028 expected | non-small cell lung carcinoma | University of Nebraska | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06795412 Background | Apr 2025 → Dec 2027 expected | cancer | Pyxis Oncology, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06877650 Background | Apr 2025 → Mar 2028 expected | cancer | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06896396 Background | Apr 2025 → Jun 2027 expected | hepatocellular carcinoma | Zhiyong Huang | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05669352 Background | Apr 2025 → Aug 2026 | metastatic malignant neoplasm in the brain | University of Florida | Suspended | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06784648 Background | Dec 2024 → Dec 2025 overdue | cutaneous melanoma, metastatic melanoma, uveal melanoma | BioInvent International AB | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06134375 Background | Nov 2024 → Jun 2031 expected | triple-negative breast carcinoma | Dartmouth-Hitchcock Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06483334 Background | Jul 2024 → Mar 2028 expected | urothelial carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05849480 Background | May 2024 → Jun 2040 expected | bile duct cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06385080 Background | Apr 2024 → Dec 2032 expected | head and neck squamous cell carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06228326 Background | Apr 2024 → Feb 2027 expected | non-small cell lung carcinoma | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06162221 Background | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06016920 Background | Dec 2023 → Sep 2027 expected | oropharynx squamous cell carcinoma | Nykode Therapeutics ASA | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05877430 Background | Sep 2023 → Jul 2026 overdue | head and neck squamous cell carcinoma, melanoma, metastatic malignant neoplasm, non-small cell lung carcinoma | CJ Bioscience, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05845814 Comparator | Jun 2023 → May 2027 expected | urothelial carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05789082 Background | Jun 2023 → Jan 2032 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05256745 Background | Jun 2023 → Dec 2026 expected | breast cancer, subjective cognitive decline | Georgetown University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05705466 Background | Jun 2023 → Jun 2025 | non-small cell lung carcinoma | Kartos Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04954599 Background | May 2023 → Feb 2027 expected | cancer of unknown primary site | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05838729 Background | Apr 2023 → Sep 2026 expected | head and neck cancer | Coordination Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05440708 Background | Mar 2023 → Feb 2027 expected | hepatocellular carcinoma | Tvardi Therapeutics, Incorporated | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05383170 Background | Mar 2023 → Sep 2024 | breast cancer, head and neck squamous cell carcinoma, melanoma | Cytovation AS | Completed | No outcome recorded |
| Phase 1/2 | NCT05482893 Background | Mar 2023 → Dec 2027 expected | biliary tract cancer, pancreatic ductal adenocarcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05469178 Background | Mar 2023 → Apr 2025 | non-small cell lung carcinoma | BerGenBio ASA | Terminated | No outcome recorded |
| Phase 1/2 | NCT05585320 Background | Oct 2022 → Jun 2026 overdue | cutaneous melanoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Immuneering Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05620134 Background | Oct 2022 → Oct 2025 overdue | clear cell renal carcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, gastroesophageal cancer +13 | Salubris Biotherapeutics Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05514990 Background | Oct 2022 → Dec 2026 expected | plasma cell myeloma | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05363631 Background | Sep 2022 → Dec 2026 expected | clear cell renal carcinoma | Mohammed Milhem | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05431270 Background | Aug 2022 → Dec 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05271318 Background | May 2022 → Mar 2027 expected | chemotherapy-induced toxicity, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | TILT Biotherapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05207722 Background | Apr 2022 → Feb 2024 | gastroesophageal junction adenocarcinoma | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 1/2 | NCT05127590 Background | Mar 2022 → Nov 2023 | non-small cell squamous lung carcinoma | Ribon Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05098132 Background | Jan 2022 → Jan 2029 expected | non-small cell lung carcinoma | Synthekine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05898763 Background | Sep 2021 → Apr 2024 | non-small cell lung carcinoma | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04946370 Background | Aug 2021 → Oct 2027 expected | prostate cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04787042 Background | Aug 2021 → Jun 2025 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma +1 | Simcha IL-18, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04977453 Background | Aug 2021 → Jun 2028 expected | cervical cancer, clear cell renal carcinoma, metastatic neoplasm, non-small cell squamous lung carcinoma +1 | GI Innovation, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04913337 Background | Jun 2021 → Feb 2025 | breast cancer, cholangiocarcinoma, colorectal cancer, endocervical carcinoma +10 | NGM Biopharmaceuticals, Inc | Unknown | No outcome recorded |
| Phase 1/2 | NCT04216316 Background | Apr 2021 → Mar 2024 overdue | non-small cell squamous lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04717375 Background | Apr 2021 → Jul 2025 | cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT04454528 Comparator | Dec 2020 → Aug 2026 overdue | breast cancer | Abramson Cancer Center at Penn Medicine | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04585750 Background | Oct 2020 → Aug 2026 overdue | HER2 positive breast carcinoma, colorectal cancer, endometrial cancer, gallbladder cancer +8 | PMV Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04140526 Background | Sep 2020 → Jun 2026 overdue | adenoid cystic carcinoma, breast cancer, cervical cancer, colorectal cancer +14 | OncoC4, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04546074 Background | Sep 2020 → Oct 2024 | melanoma | Keio University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04521413 Background | Aug 2020 → Nov 2025 overdue | high grade malignant neoplasm | Treadwell Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04561362 Background | Jul 2020 → Mar 2026 overdue | hormone receptor-positive breast cancer, non-small cell lung carcinoma, ovarian neoplasm, triple-negative breast carcinoma +1 | BicycleTx Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04219254 Background | Jun 2020 → Nov 2027 expected | cancer | BioInvent International AB | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04305041 Background | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04333004 Background | Apr 2020 → Apr 2021 | non-small cell lung carcinoma | Xiaorong Dong | Unknown | No outcome recorded |
| Phase 1/2 | NCT03983668 Background | Jan 2020 → Aug 2024 | lymphoma | Umar Farooq | Terminated | No outcome recorded |
| Phase 1/2 | NCT04180215 Background | Dec 2019 → Jan 2025 | human papillomavirus-related squamous cell carcinoma | Hookipa Biotech GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT04083599 Background | Sep 2019 → Dec 2025 overdue | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma +1 | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03970746 Background | Sep 2019 → Jul 2024 overdue | non-small cell lung carcinoma | PDC*line Pharma SAS | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03747484 Background | Jul 2019 → Jan 2024 | — | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03917381 Background | May 2019 → Apr 2025 overdue | cancer | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03834948 Background | Feb 2019 → Nov 2022 | neoplasm | Arch Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03476681 Background | Jan 2019 → Jun 2026 overdue | cervical cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Precision Biologics, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02842125 Background | Nov 2018 → May 2020 | head and neck squamous cell carcinoma, metastatic malignant neoplasm | MultiVir, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03781934 Background | Sep 2018 → Jan 2025 | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Medivir | Completed | No outcome recorded |
| Phase 1/2 | NCT03633110 Background | Aug 2018 → Dec 2021 | cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, renal cell carcinoma +1 | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03556228 Background | Jun 2018 → Dec 2027 expected | adenoid cystic carcinoma, esophageal cancer, head and neck squamous cell carcinoma, hypopharynx cancer +10 | VM Oncology, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03416335 Background | Jun 2018 → Dec 2022 | neoplasm | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03526835 Background | May 2018 → Nov 2025 overdue | colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +2 | Merus B.V. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03525782 Comparator | Feb 2018 → Jan 2021 | non-small cell lung carcinoma | The First Affiliated Hospital of Guangdong Pharmaceutical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03371979 Background | Dec 2017 → Jan 2021 | small cell lung carcinoma | Aeglea Biotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT03277352 Background | Nov 2017 → Jul 2020 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03009058 Background | May → Aug 2017 | metastatic malignant neoplasm | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT03085914 Background | May 2017 → Jan 2019 | cancer | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02872259 Comparator | Feb 2017 → May 2024 | melanoma | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02713529 Background | Apr 2016 → Jan 2019 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | AmMax Bio, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02408042 Comparator | Apr → Nov 2015 | Hodgkins lymphoma, non-Hodgkin lymphoma | Western Regional Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02430363 Comparator | Mar 2013 → Jan 2016 | glioblastoma | Medical Research Council | Unknown | No outcome recorded |
| Phase 1/2 | NCT01433172 Comparator | Mar 2012 → Jan 2016 | adenocarcinoma, lung cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2116 trials | ||||||
| Phase 2 | NCT07610525 Background | Nov 2026 → Jan 2029 expected | triple-negative breast carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07691645 Background | Sep 2026 → Aug 2029 expected | hepatocellular carcinoma | Xiang-Qian | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05106127 Background | Aug 2026 → Mar 2027 expected | endometrial cancer | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07452224 Background | Jun 2026 → Jun 2029 expected | non-small cell lung carcinoma | iLeukon Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07618793 Background | Jun 2026 → Dec 2027 expected | non-small cell squamous lung carcinoma | zhang yi | Not yet recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 2/316 trials | ||||||
| Phase 2/3 | NCT07365319 Background | Jun 2026 → Dec 2035 expected | non-small cell lung carcinoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07318883 Comparator | Mar 2026 → Jan 2031 expected | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07063745 Comparator | Jan 2026 → Aug 2031 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06947928 Background | Dec 2025 → Mar 2027 expected | cutaneous neuroendocrine carcinoma | TuHURA Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06841679 Background | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06788990 Background | Jan 2025 → Apr 2028 expected | head and neck squamous cell carcinoma | Bicara Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06712316 Comparator | Jan 2025 → Feb 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06082167 Background | Jun 2024 → Aug 2028 expected | head and neck squamous cell carcinoma | Exelixis | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06984588 Comparator | Mar 2024 → Aug 2028 expected | non-small cell lung carcinoma | TJ Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05987332 Comparator | Oct 2023 → Jan 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05429697 Comparator | Jun 2022 → Jan 2025 | biliary tract cancer | SMT bio Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04887870 Background | Jun 2021 → Apr 2025 | cancer of unknown primary site | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04619797 Comparator | Dec 2020 → Apr 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/3 | NCT04613596 Comparator | Dec 2020 → Oct 2028 expected | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05809336 Background | May 2019 → Oct 2022 | neoplasm | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02784171 Comparator | Nov 2016 → Oct 2024 | mesothelioma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 3116 trials | ||||||
| Phase 3 | NCT05077215 Background | Dec 2026 → Dec 2027 expected | endometrial cancer | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07715396 Comparator | Oct 2026 → Oct 2031 expected | non-small cell lung carcinoma | AIO-Studien-gGmbH | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07578649 Comparator | Oct 2026 → Jun 2029 expected | endometrial cancer | Pfizer | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07684599 Comparator | Sep 2026 → Jul 2029 expected | endometrial cancer | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07541170 Comparator | Sep 2026 → Jan 2032 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 44 trials | ||||||
| Phase 4 | NCT06903312 Comparator | Jun 2025 → Oct 2027 expected | renal cell carcinoma | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 4 | NCT06824792 Background | Mar 2025 → Feb 2028 expected | cancer | NING LI | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05689671 Comparator | Dec 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Nikolaj Frost MD | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05235737 Comparator | Mar 2022 → Jun 2025 | glioblastoma | Medical University of Silesia | Unknown | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07629700 Background | Sep 2026 → Sep 2027 expected | peripheral neuropathy, urothelial carcinoma | University of Florence | Not yet recruiting | No outcome recorded |
| — | NCT06876636 Background | Mar → Dec 2025 overdue | breast carcinoma | Xijing Hospital | Active not recruiting | No outcome recorded |
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT07436390 Background | Mar 2024 | metastatic melanoma, skin cancer | Institute of Oncology Ljubljana | Completed | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT06000358 Comparator | Apr 2023 → Mar 2026 | lung carcinoma | Lithuanian University of Health Sciences | Unknown | No outcome recorded |
| — | NCT05233358 Background | Feb 2022 → Feb 2023 | hepatocellular carcinoma | The Central Hospital of Lishui City | Unknown | No outcome recorded |
| — | NCT05821751 Background | Dec 2021 → Dec 2024 | head and neck squamous cell carcinoma | Fondazione del Piemonte per l'Oncologia | Unknown | No outcome recorded |
| — | NCT04924374 Comparator | Apr 2021 → Nov 2023 | lung cancer | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| — | NCT04453046 Background | Oct 2020 → Nov 2022 | head and neck squamous cell carcinoma | Aethlon Medical Inc. | Terminated | No outcome recorded |
| — | NCT07537985 Background | Jan 2020 → Aug 2025 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05389514 Background | — | — | Providence Health & Services | Temporarily not available | No outcome recorded |
Press releases naming this drug 128 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | AstraZeneca | Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy astrazeneca.com ↗ |
| 2026-07-24 | Gilead Sciences | CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer gilead.com ↗ |
| 2026-07-10 | Pfizer | U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-06-26 | AstraZeneca | Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy astrazeneca.com ↗ |
| 2026-05-28 | AstraZeneca | Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. astrazeneca.com ↗ |
| 2026-04-20 | Pfizer | U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-03-16 | AstraZeneca | Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers astrazeneca.com ↗ |
| 2026-02-27 | Pfizer | PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer pfizer.com ↗ |
| 2026-02-03 | AstraZeneca | Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy astrazeneca.com ↗ |
| 2026-01-21 | Gilead Sciences | New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer gilead.com ↗ |
| 2026-01-21 | BioNTech SE | BioNTech Receives FDA Fast Track Designation for mRNA Cancer Immunotherapy Candidate BNT113 in HPV16+ Head and Neck Cancer biontech.com ↗ |
| 2025-12-17 | Pfizer | PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| Show all 128 releases opens the full record — a long page | ||
Evidence & citations 63 cited values
Every value below carries the sentence it was read from. 2,632 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab | “The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and...” NCT06307093 ↗2547“1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ “Standard of Care Drugs (at investigator's discretion) may include: pembrolizumab, nivolumab, cemiplimab, durvalumab, dostarlimab, avelumab, and atezolizumab, or other immune...” NCT07224971 ↗ “All patients will receive a one-cycle lead-in of carboplatin (with or without) paclitaxel followed by three cycles of carboplatin, paclitaxel, and pembrolizumab prior to...” NCT05952453 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗ “This investigator driven pilot study will examine the safety and biological effects of combining MK-3475 (Pembrolizumab) an antibody targeted against the anti-programmed cell...” NCT02303366 ↗ “A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage...” NCT06268613 ↗ “IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗ “Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or...” NCT06903312 ↗ “The anti-PD-1 agent, pembrolizumab, received recent FDA accelerated approval for the use in patients with metastatic MSI-H or dMMR solid tumors that have progressed following...” NCT04001101 ↗ “In this pilot study, the investigators will investigate if Nilogen's functional ex vivo bioassay can predict therapeutic response to anti PD1 (nivolumab, pembrolizumab) or anti...” NCT03371992 ↗ “Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist...” NCT05846659 ↗ “PD-L1 inhibitor Drug: Durvalumab OR pembrolizumab Durvalumab: During combination therapy: 1500 mg, Q3W, during combination therapy, on days 3-5 of each 3-week cycle (determined...” NCT07364305 ↗ “TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab,...” NCT02890368 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease...” NCT06731413 ↗ “Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally...” NCT06550453 ↗ “Participants receive pembrolizumab 200 mg every 3 weeks (Dose Finding Component) or a disease appropriate PD1/PD-L1 inhibitor (Dose Expansion Component) for 2 treatment courses...” NCT05338658 ↗ “Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its...” NCT03114280 ↗ “Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following...” NCT04670107 ↗ “This phase I study aimed to assess the safety and clinical activity of immunotherapy with PD-1 blockade (pembrolizumab)-activated autologous DC-CIK cells in patients with...” PMID 29632736 ↗ Jan 2018 “The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once...” NCT06728657 ↗ “ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab.” NCT03523702 ↗ “Current treatments include anti-CD30 (Brentuximab-Vedotin) and PD-1 inhibitors (Nivolumab or Pembrolizumab), often in combination with Autologous Stem Cell Transplantation (ASCT).” PMID 41522540 ↗ Feb 2025 “total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .” NCT03815084 ↗ “autologous bone marrow-derived dendritic cells (Cellgram-DC-WT1) made by isolating CD141+ cells from the bone marrow are administered intravenously together with pembrolizumab” NCT06172634 ↗ “Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year.” NCT02828098 ↗ “The PD-1 inhibitor component is not fixed; specific agents (such as pembrolizumab, sintilimab, etc.) may be used according to institutional standards and drug availability.” NCT07417501 ↗ “Multimodal ablation combined with pembrolizumab or toripalimab, with other specific agents determined based on the first-line treatment regimen and the melanoma subtype.” NCT06889610 ↗ “Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)” NCT03313804 ↗ “therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab, or currently approved standard of care treatment, either alone or in combination” NCT05358938 ↗ “Examples include PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab, camrelizumab, sintilimab) Administered per standard dosing schedule (e.g., every 2-3 weeks)” NCT07277777 ↗ “mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer” NCT05916261 ↗ “BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks” NCT03638297 ↗ “ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.” NCT06983743 ↗ “Patients received four cycles of intravenous pembrolizumab 200 mg on day 1 and intravenous sacituzumab govitecan 7·5 mg/kg on day 1 and day 8, every 3 weeks” PMID 41771275 ↗ Feb 2026 “with addition of anti-PD-1 antibody KEYTRUDA® (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.” NCT03058289 ↗ “PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.” NCT05838729 ↗ “Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W” NCT06170710 ↗ “A Phase I/II, Open-Label, Dose Escalation and Expansion Study of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors” NCT05255484 ↗ “Clinical trials have shown that PD-1 inhibitors (such as pembrolizumab and nivolumab) can shrink tumours and extend the life of patients with melanoma.” NCT02821013 ↗ “Patients receive standard induction chemoimmunotherapy (carboplatin, paclitaxel, and pembrolizumab) in three 21-day cycles, beginning on Day 1.” NCT07335380 ↗ “Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations” NCT04399876 ↗ “Specific agent (e.g., Pembrolizumab, Durvalumab, Toripalimab, or Tislelizumab) may be chosen based on local availability and patient access.” NCT07282262 ↗ “If a PD-1 inhibitor is administered in combination, tislelizumab (200 mg), or pembrolizumab (200 mg), or nivolumab (360 mg), iv, day1, q3w.” NCT06841679 ↗ “Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.” NCT03757858 ↗ “All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off and 200 mg of intravenous pembrolizumab every 3 weeks.” PMID 28662235 ↗ Jan 2018 “Combination of a PD-1 inhibitor (e.g., Pembrolizumab or Nivolumab) with CAPOX or FOLFOX chemotherapy for a specified number of cycles.” NCT07214142 ↗ “Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.” NCT04997382 ↗ “Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.” NCT03360630 ↗ “Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.” NCT03393858 ↗ “Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.” NCT03190811 ↗ “Pembrolizumab (Keytruda) the programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response.” NCT05048017 ↗ “The objective is to evaluate the efficacy and safety of Olinvacimab in combination with Pembrolizumab in patients with mTNBC.” NCT04986852 ↗ “treatment will consist of single-agent pembrolizumab in combination with physician's choice platinum-doublet chemotherapy” NCT05303493 ↗ “PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab, Nivolumab), 200mg/dose, iv drip, q3w.” NCT07537985 ↗ “Patients with metastatic malignant melanoma treated in the first line with PD-1 inhibitors (pembrolizumab or nivolumab).” NCT07428252 ↗ “weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide” NCT05256745 ↗ “Pembrolizumab is a biologic drug (produced by living organisms) available in the market under the brand name Keytruda.” NCT06643117 ↗ “Pembrolizumab is a biologic drug (produced by living organisms) available in the market under the brand name Keytruda.” NCT06551064 ↗ “intravenous (IV) pembrolizumab 200 mg flat dose with IV pegylated liposomal doxorubicin (PLD) 30 mg/m2, every 3 weeks.” NCT03591276 ↗ “All participants will receive three 21-day cycles of carboplatin, paclitaxel, and pembrolizumab as induction therapy.” NCT07428148 ↗ “Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on” NCT06032052 ↗ “Immunotherapy, with agents including but not limited to ramucirumab, pembrolizumab, camrelizumab, and tislelizumab.” NCT07691645 ↗ “FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors” NCT04699643 ↗ “Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab.” NCT05233358 ↗ “PD-1 inhibitors in this study include, but not limited to, Pembrolizumab, nivolumab, sintilimab, toripalimab, etc.” NCT05509478 ↗ “The PD-1 inhibitor (e.g., pembrolizumab) will be used exclusively in Cohort 1 in combination with vebrekotuzumab.” NCT07403136 ↗ “Axitinib 5 mg was administered orally twice per day with pembrolizumab 2 mg/kg given intravenously every 3 weeks.” PMID 29439857 ↗ Feb 2018 “Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).” NCT05898763 ↗ “9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled” NCT06643910 ↗ “PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab), 200mg/dose, iv drip, q3w.” NCT07501351 ↗ “investigator's choice of immune checkpoint inhibitor [nivolumab, pembrolizumab, or atezolizumab] or docetaxel” PMID 37657460 ↗ Sep 2023 “Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)” NCT07485296 ↗ “PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.” NCT06702566 ↗ “Pembrolizumab will be administered with the standard regimen of 400 mg intravenously (IV) every six weeks.” NCT05425576 ↗ “Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab” NCT06084897 ↗ “Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.” NCT04219254 ↗ “Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab” NCT06535893 ↗ “part A2 (dose-escalation cohorts with the combination treatment of linavonkibart and pembrolizumab)” PMID 41530380 ↗ Jan 2026 “Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle” NCT06567600 ↗ “Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W.” NCT06121700 ↗ “Pembrolizumab, an FDA-approved antibody against PD-1/PD-L1, has a well-established safety profile” NCT05806385 ↗ “Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care” NCT05902260 ↗ “Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.” NCT04997837 ↗ “All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.” NCT04045730 ↗ “Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).” NCT05849480 ↗ “single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel” NCT05222087 ↗ “combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment” NCT06110793 ↗ “Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody)” NCT05277402 ↗ “Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks” NCT06211114 ↗ “Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.” NCT05438459 ↗ “OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab.” NCT07040436 ↗ “Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes for every two month” NCT06676293 ↗ “administration of Pembrolizumab for patients with high rosatellite instability (MSI-H)” NCT06555003 ↗ “Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab).” NCT06840782 ↗ “200 mg Pembrolizumab (MK-3475) i.v. in 3-week cycle (q3w) for 17 cycles (12 months).” NCT06137378 ↗ “Four cycles of an intravenous infusion of pembrolizumab (200 mg) once every 3 weeks” NCT06831955 ↗ “either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab” NCT05069935 ↗ “Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab” NCT06074029 ↗ “Treatment will consist of "QUAD SHOT" radiotherapy combined with pembrolizumab.” NCT04373642 ↗ “The ICI will be either nivolumab or pembrolizumab and dosing will be per SOC.” NCT06063681 ↗ “Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks” NCT03938337 ↗ “Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.” NCT05127590 ↗ “added to pembrolizumab, intravenously, at the dose of 200 mg every 21 days” NCT06341478 ↗ “Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)” NCT05207371 ↗ “Pembrolizumab, Sintilimab etc. have been used in the previous treatment.” NCT04322617 ↗ “Food and Drug Administration (FDA)-licensed pembrolizumab (Keytruda-US)” NCT06153238 ↗ “pembrolizumab 200 mg, camrelizumab 200 mg, or toripalimab 240 mg IV q3w” NCT06145308 ↗ “e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab” NCT06896422 ↗ “regimen includes: 1) Nab-paclitaxel; 2) Carboplatin; 3) Pembrolizumab.” NCT07618793 ↗ “pembrolizumab 200 mg on Day 1 q3w or toripalimab 240 mg on Day 1 q3w” NCT06876636 ↗ “the immunotherapy (pembrolizumab and nivolumab versus atezolizumab)” NCT05111197 ↗ “Pembrolizumab (Keytruda) + Preoperative Stereotactic Radiotherapy.” NCT06472583 ↗ “versus Keytruda (pembrolizumab) when administered as monotherapy” NCT07475572 ↗ “Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)” NCT03035890 ↗ “Maintenance: Pemetrexed (500mg/m²) + pembrolizumab 200mg IV q3w.” NCT07014202 ↗ “Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle” NCT05512182 ↗ “Pembrolizumab, also known as MK-3475, at different dose levels” NCT03345134 ↗ “MK-3475 (generic name: pembrolizumab, trade name Keytruda®).” NCT02289209 ↗ “PD-1 Inhibitor (e.g.pembrolizumab, Sintilimab,Camrelizumab )” NCT05322187 ↗ “Pembrolizumab (MK-3475) is a humanized monoclonal antibody.” NCT02852655 ↗ “PD-1 inhibitor (Pembrolizumab) 200mg iv day1, every 3 weeks” NCT05218629 ↗ “Pembrolizumab 200mg once every 3 weeks until progression” NCT05589961 ↗ “Pembrolizumab will be given every 6 weeks for 18 cycles” NCT07662720 ↗ “Rh-endostatin+Pembrolizumab+carboplatin or cisplatin” NCT04094909 ↗ “Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat” NCT05774886 ↗ “pembrolizumab, a monoclonal antibody binding PD-1” NCT06125197 ↗ “Toripalimab, Pembrolizumab and Camrelizumab, etc.” NCT06802757 ↗ “Pembrolizumab iv infusion 2 mg/kg every 3rd week” NCT04644432 ↗ “either pembrolizumab, atezolizumab or cemiplimab” NCT05344209 ↗ “pembrolizumab 200 mg intravenous every 3 weeks” NCT05467748 ↗ “Keytruda (pembrolizumab) via IV administration” NCT07021898 ↗ “PD-1 inhibitor (pembrolizumab) 200mg iv day 1” NCT05267366 ↗ “Pembrolizumab 200mg 6 weekly (up to 2 years)” NCT06422403 ↗ “Pembrolizumab + Gemcitabine + Carboplatin” NCT06135714 ↗ “Immunotherapy: nivolumab or pembrolizumab” NCT07000253 ↗ “Pembrolizumab, Nivolizumab, Atezolizumab” NCT04924374 ↗ “Single dose of Pembrolizumab 200 mg IV” NCT07388550 ↗ “intravenous infusions of Pembrolizumab” NCT03818893 ↗ “Pembrolizumab q3W in combination with” NCT06358573 ↗ “Pembrolizumab (Keytruda®) Monotherapy” NCT07574047 ↗ “Pembrolizumab 200 mg IV 1 q 3 weeks” NCT04510597 ↗ “Pembrolizumab 200mg/3 weeks, iv, D1” NCT06888037 ↗ “Pembrolizumab 200 mg every 3 weeks” NCT07130032 ↗ “Pembrolizumab 200mg every 3 weeks” NCT06388031 ↗ “Main ingredient: Pembrolizumab” NCT06400160 ↗ “Pembrolizumab (Keytruda), OR” NCT02423863 ↗ “Nivolumab and pembrolizumab” NCT05108623 ↗ “KEYTRUDA ®( Pembrolizumab)” NCT05970497 ↗ “Keytruda® (Pembrolizumab)” NCT07162883 ↗ “Pembrolizumab (KEYTRUDA®)” NCT04648202 ↗ “Pembrolizumab: 200mg/dose” NCT05916248 ↗ “pembrolizumab (KEYTRUDA),” NCT03009058 ↗ “anti-PD-1 (Pembrolizumab)” NCT04951583 ↗ “pembrolizumab (Keytruda)” NCT04079166 ↗ “Keytruda (pembrolizumab)” NCT04157985 ↗ “Pembrolizumab injection” NCT05809336 ↗ “Drug: Pembrolizumab” NCT05567588 ↗ “Drug: Pembrolizumab” NCT03872947 ↗ “Drug: Pembrolizumab” NCT07639242 ↗ “Pembrolizumab” NCT04986852 ↗ “Pembrolizumab” NCT03189186 ↗ “Pembrolizumab” NCT05676749 ↗ “Pembrolizumab” NCT06667167 ↗ “pembrolizumab” NCT05846646 ↗ “Pembrolizumab” NCT05704985 ↗ “Pembrolizumab” NCT05008861 ↗ “Pembrolizumab” NCT04936841 ↗ “Pembrolizumab” NCT04954599 ↗ “pembrolizumab” NCT04009681 ↗ “Pembrolizumab” NCT06031597 ↗ “pembrolizumab” NCT03544723 ↗ “Pembrolizumab” NCT04849364 ↗ |
| Known as | 1374853-91-4 | “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ |
| Known as | 2LALERG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02690935 ↗ |
| Known as | [177Lu]Lu-RTX-2358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07689643 ↗ |
| Known as | AT1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285395 ↗ |
| Known as | BCD-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05739006 ↗ |
| Known as | Boiled Peanut Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04090203 ↗ |
| Known as | Bystander-Based Autologous Tumor Cell Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101166 ↗ |
| Known as | C-TIL051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05676749 ↗ |
| Known as | CMV specific adoptive t-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982902 ↗ |
| Known as | Coformulated favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845814 ↗ |
| Known as | Coformulated vibostolimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845814 ↗ |
| Known as | Coformulation favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05342636 ↗ |
| Known as | Duvarizumab | “PD-L1 inhibitor (Duvarizumab)” NCT05322187 ↗ |
| Known as | EBNK-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410676 ↗ |
| Known as | EVER4010001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04699643 ↗ |
| Known as | FB849 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761223 ↗ |
| Known as | GM.CD40L | “In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8...” NCT00840931 ↗ |
| Known as | Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02539017 ↗ |
| Known as | Ipilumimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01996202 ↗ |
| Known as | Keytruda | “The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and...” NCT06307093 ↗166“The goal of this double-blind, randomized study is to establish the equivalence of the efficacy, safety and immunogenicity of the drugs RPH-075 (international nonproprietary...” NCT06320353 ↗ “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ “The primary objectives of this study are to evaluate the safety and tolerability of BDB018 in monotherapy and in combination with pembrolizumab (Keytruda) in subjects with...” NCT04840394 ↗ “Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting...” NCT04244552 ↗ “The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the...” NCT05033756 ↗ “The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in...” NCT03087760 ↗ “A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery...” PMID 33529989 ↗ Jan 2021 “The primary objective of ELOS is to compare laryngectomy-free survival (LFS) achieved by adding KEYTRUDA® (pembrolizumab) to standard treatment and LFS after standard treatment...” NCT06137378 ↗ “This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in...” NCT06532812 ↗ “Pembrolizumab is an investigational drug (also known as Keytruda), which has been approved by the FDA for use in certain types of skin cancer (melanoma), and for use in certain...” NCT02987998 ↗ “Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗ “The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers.” NCT06173011 ↗ “A Phase 1b Study of Combination Chemo-immunotherapy With Pegylated Liposomal Doxorubicin (Doxil/Caelyx) and Pembrolizumab (Keytruda) in Metastatic Endocrine-resistant Breast Cancer” NCT03591276 ↗ “A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)” NCT03192059 ↗ “total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .” NCT03815084 ↗ “One cohort in which MBS8(1V270) will be evaluated in combination with pembrolizumab (Keytruda) in cutaneous melanoma patients with acquired resistance to PD-1 therapy;” NCT04855435 ↗ “Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy.” NCT04857164 ↗ “H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)” NCT07484139 ↗ “Pembrolizumab (Keytruda), an immunotherapy targeting the PD-1 receptor on T cells, is also given to further enhance the immune response against the tumor.” NCT06640582 ↗ “Pembrolizumab (Keytruda), an immunotherapy targeting the PD-1 receptor on T cells, is also given to further enhance the immune response against the tumor.” NCT06538012 ↗ “KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.” NCT06022757 ↗ “pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults” NCT03515837 ↗ “Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.” NCT03197389 ↗ “400 mg of pembrolizumab (KEYTRUDA) will be given by IV every 6 weeks for 9 cycles, for approximately one year of study drug administration.” NCT04569461 ↗ “The treatment pembrolizumab KEYTRUDA® will be administered as a 30-minute IV infusion at a dose of 200 mg on Day 1 of every 21-day cycle.” NCT05082610 ↗ “Pembrolizumab (KEYTRUDA®) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.” NCT04613596 ↗ “Pembrolizumab, also known as KEYTRUDA or MK-3475, is approved in the USA and several other countries to treat other types of diseases.” NCT02971956 ↗ “Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle.” NCT05215574 ↗ “Pembrolizumab (Keytruda) the programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response.” NCT05048017 ↗ “in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors” NCT05746897 ↗ “Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery.” NCT06180733 ↗ “ADG116 combination treatment with pembrolizumab (KEYTRUDA®), both drugs will be administered in each cohort.” NCT05277402 ↗ “participants will be dosed with pembrolizumab(KEYTRUDA®) first, administered over 0.5 hours (± 10 minutes).” NCT05957081 ↗ “Pembrolizumab (Keytruda), an immunotherapy that targets the PD-1 receptor on T cells, is also administered” NCT06532799 ↗ “Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).” NCT05405595 ↗ “1. Keytruda, (L01XC18), pembrolizumab, intravenous administration (administered as standard of care).” NCT07645625 ↗ “Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications” NCT06302569 ↗ “Pembrolizumab (commercial name: KEYTRUDA; MSD), 25 mg/ml solution for intravenous (IV) injection” NCT06276504 ↗ “Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle” NCT03562871 ↗ “Pembrolizumab (Keytruda™) is a potent and highly selective humanized monoclonal antibody” NCT03665545 ↗ “200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months” NCT06726265 ↗ “* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)” NCT03720431 ↗ “Pembrolizumab (Keytruda) is approved for use in more than ten types of cancer.” NCT06794645 ↗ “Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)” NCT03722342 ↗ “Pembrolizumab (Keytruda) and Aldesleukin (interleukin-2, IL-2) immunotherapy” NCT06530303 ↗ “* Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)” NCT04986852 ↗ “Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)” NCT05207371 ↗ “Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)” NCT06430866 ↗ “Anti-PD1 antibody pembrolizumab (Keytruda, Merck) will be infused day 12” NCT03804944 ↗ “PEMBROLIZUMAB (Keytruda®) With Chemotherapy Versus Chemotherapy Alone” NCT03275506 ↗ “Drug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218” NCT05859464 ↗ “pembrolizumab (KEYTRUDA®) will be administered intravenously (IV)” NCT04913337 ↗ “I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles” NCT06407310 ↗ “MK-3475 (generic name: pembrolizumab, trade name Keytruda®).” NCT02289209 ↗ “Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection” NCT04752826 ↗ “Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]” NCT03480672 ↗ “Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]” NCT04188951 ↗ “Total dose of 10ml Keytruda will be administered at day0” NCT03815630 ↗ “concomitant Pembrolizumab (Keytruda) and ECT treatments” NCT03448666 ↗ “Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)” NCT03666273 ↗ “KEYTRUDA® (pembrolizumab) will be administered Q6W” NCT05394103 ↗ “pembrolizumab (Keytruda) in the front line setting” NCT04453046 ↗ “Pembrolizumab KEYTRUDA® administered intravenously” NCT05280314 ↗ “Keytruda (pembrolizumab) 200 mg IV every 3 weeks” NCT03043664 ↗ “pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.” NCT03625323 ↗ “pembrolizumab (an antibody known as KEYTRUDA®)” NCT06635824 ↗ “Pembrolizumab 50 MG Injection [Keytruda]” NCT06045767 ↗ “GV20-0251 and Pembrolizumab [KEYTRUDA®]” NCT05669430 ↗ “Pembrolizumab (KEYTRUDA) 200 mg IV Q3W” NCT06270706 ↗ “Pembrolizumab (Keytruda®) Monotherapy” NCT07574047 ↗ “Pembrolizumab (KEYTRUDA®) and PDS0101” NCT04260126 ↗ “IOS-1002 + KEYTRUDA® (pembrolizumab)” NCT05763004 ↗ “Pembrolizumab Injection [Keytruda]” NCT04303884 ↗ “ANV600 + pembrolizumab (KEYTRUDA®)” NCT06470763 ↗ “Pembrolizumab Injection [Keytruda]” NCT04863079 ↗ “Pembrolizumab Injection [Keytruda]” NCT04389177 ↗ “Pembrolizumab Injection [Keytruda]” NCT03189186 ↗ “TU2218 + KEYTRUDA® (Pembrolizumab)” NCT05784688 ↗ “Pembrolizumab Injection [Keytruda]” NCT03937895 ↗ “Pembrolizumab Injection [Keytruda]” NCT05096390 ↗ “Pembrolizumab Injection [Keytruda]” NCT03563729 ↗ “Pembrolizumab Injection [Keytruda]” NCT04813523 ↗ “Pembrolizumab Injection [Keytruda]” NCT04931979 ↗ “Pembrolizumab 25 MG/ML [Keytruda]” NCT04602377 ↗ “pembrolizumab 200 mg (KEYTRUDA ®)” NCT06116136 ↗ “Pembrolizumab 25 MG/ML [Keytruda]” NCT05085028 ↗ “Pembrolizumab 25 MG/ML [Keytruda]” NCT05563467 ↗ “Drug: KEYTRUDA® (pembrolizumab)” NCT05482893 ↗ “Other Name: MK-3475; Keytruda” NCT04753879 ↗ “Pembrolizumab (Keytruda), OR” NCT02423863 ↗ “Pembrolizumab (KEYTRUDA® )” NCT06697301 ↗ “KEYTRUDA ®( Pembrolizumab)” NCT05205109 ↗ “KEYTRUDA ®( Pembrolizumab)” NCT06963814 ↗ “pembrolizumab (KEYTRUDA® )” NCT07262619 ↗ “Pembrolizumab (KEYTRUDA ®)” NCT07264075 ↗ “Pembrolizumab (KEYTRUDA ®)” NCT05929235 ↗ “Pembrolizumab (KEYTRUDA ®)” NCT05311618 ↗ “Pembrolizumab (KEYTRUDA®)” NCT07365319 ↗ “Pembrolizumab (KEYTRUDA®)” NCT06788990 ↗ “KEYTRUDA® (pembrolizumab)” NCT05597839 ↗ “Pembrolizumab (KEYTRUDA®)” NCT03311308 ↗ “Pembrolizumab (Keytruda®)” NCT04095273 ↗ “Pembrolizumab (KEYTRUDA®)” NCT07188246 ↗ “KEYTRUDA® (pembrolizumab)” NCT04130542 ↗ “Keytruda® (pembrolizumab)” NCT05585034 ↗ “Pembrolizumab (KEYTRUDA®)” NCT06228326 ↗ “Pembrolizumab (Keytruda®)” NCT03849469 ↗ “pembrolizumab (KEYTRUDA®)” NCT04811027 ↗ “Pembrolizumab (KEYTRUDA®)” NCT03126591 ↗ “KEYTRUDA® (pembrolizumab)” NCT07158918 ↗ “Pembrolizumab (KEYTRUDA®)” NCT06736379 ↗ “pembrolizumab (KEYTRUDA®)” NCT03674567 ↗ “pembrolizumab (KEYTRUDA®)” NCT06784648 ↗ “Pembrolizumab (KEYTRUDA®)” NCT06805864 ↗ “pembrolizumab (KEYTRUDA®)” NCT04993677 ↗ “Keytruda® (pembrolizumab)” NCT05996445 ↗ “Pembrolizumab (KEYTRUDA®)” NCT04648202 ↗ “Pembrolizumab (KEYTRUDA®)” NCT06951399 ↗ “Pembrolizumab (KEYTRUDA®)” NCT05086692 ↗ “Pembrolizumab (Keytruda)” NCT03922204 ↗ “Pembrolizumab (Keytruda)” NCT03721679 ↗ “Pembrolizumab (Keytruda)” NCT01174121 ↗ “KEYTRUDA®, Pembrolizumab” NCT03978689 ↗ “Pembrolizumab (Keytruda)” NCT04262089 ↗ “pembrolizumab (Keytruda)” NCT04079166 ↗ “Pembrolizumab (Keytruda)” NCT05119296 ↗ “Pembrolizumab (Keytruda)” NCT03149029 ↗ “pembrolizumab KEYTRUDA®” NCT05098132 ↗ “Pembrolizumab/KEYTRUDA®” NCT07469774 ↗ “pembrolizumab/KEYTRUDA®” NCT07327229 ↗ “pembrolizumab KEYTRUDA®” NCT04920383 ↗ “GX-188E, KEYTRUDA®” NCT03444376 ↗ “KEYTRUDA, MK-3475” NCT02981524 ↗ “Drug: Keytruda” NCT07388550 ↗ “Keytruda” NCT03645928 ↗ “Keytruda” NCT03525782 ↗ “keytruda” NCT03716596 ↗ |
| Known as | Keytruda (pembrolizumab) | “Keytruda® (pembrolizumab)” NCT04777851 ↗ |
| Known as | KEYTRUDA(R) | “Pembrolizumab (KEYTRUDA(R))” NCT04536922 ↗1“Pembrolizumab (KEYTRUDA(R))” NCT03412877 ↗ |
| Known as | Keytruda-EU | “European Union (EU)-authorized pembrolizumab (Keytruda-EU)” NCT06153238 ↗ |
| Known as | Keytruda-Merck | “Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks” NCT05119296 ↗ |
| Known as | Keytruda-US | “Food and Drug Administration (FDA)-licensed pembrolizumab (Keytruda-US)” NCT06153238 ↗ |
| Known as | Keytruda/MK-3475 (Pembrolizumab) | “Keytruda/MK-3475 (Pembrolizumab)” NCT05832827 ↗ |
| Known as | KeytrudaTM | “KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma” NCT03114280 ↗1“KeytrudaTM (pembrolizumab) has been approved in the United States for the treatment of patients with unresectable or metastatic melanoma” NCT03879174 ↗ |
| Known as | lambrolizumab | “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗3“Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy.” NCT04857164 ↗ “Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy.” NCT04999800 ↗ “Lambrolizumab” NCT03918499 ↗ |
| Known as | melanoma vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00928902 ↗ |
| Known as | MK-3475 | “The purpose of this study is to assess the safety and efficacy of Anlotinib (AL3818) combined with pembrolizumab (MK-3475) in treatment-naïve adults with no prior systemic...” NCT04164745 ↗96“1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ “The study design initially included two treatment cohorts, with the PD-L1 negative/unknown cohort being treated with the HER2CLIMB regimen with the addition of pembrolizumab...” NCT04789096 ↗ “Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block...” NCT03082534 ↗ “This is a phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475) in patients with osteosarcoma who have experienced disease relapse or progression...” NCT03013127 ↗ “The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in...” NCT03087760 ↗ “A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery...” PMID 33529989 ↗ Jan 2021 “A Phase II Study of Perioperative mFOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially...” NCT03488667 ↗ “The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients...” NCT02305186 ↗ “A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in...” NCT03739138 ↗ “Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction...” NCT03051672 ↗ “This is phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475) in subjects with metastatic or locally advanced/unresectable or metastatic malignant...” NCT02691026 ↗ “A PHASE 1B, OPEN LABEL, DOSE FINDING STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB (AG-013736) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN...” NCT02133742 ↗ “This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing...” NCT03293680 ↗ “Exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior...” NCT03526887 ↗ “A Phase II Study of Perioperative mFOLFOX6 Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal...” NCT02943603 ↗ “Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With...” NCT02657889 ↗ “A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung...” NCT03664024 ↗ “A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid...” NCT04214067 ↗ “This is a multi-centre, single arm phase 2 study of Pembrolizumab (Keytruda™ or MK-3475) in treatment naïve patients with poor prognosis carcinoma of unknown primary site (CUP).” NCT03391973 ↗ “Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.” NCT02736266 ↗ “PRIMARY OBJECTIVES: I. To determine the recommended phase II dose (RP2D) for the combination of MK-3475 (pembrolizumab) and standard, adjuvant cisplatin-radiotherapy” NCT02775812 ↗ “A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)” NCT05286619 ↗ “Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)” NCT02083484 ↗ “Phase II Study to Test Pembrolizumab (MK-3475) in First Line Treatment of Advanced NSCLC Patients with PD-L1 Low Tumors (<50%)_ PEOPLE TRIAL” NCT03447678 ↗ “A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer” NCT02260440 ↗ “Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W” NCT03276013 ↗ “Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.” NCT07015853 ↗ “Pembrolizumab, also known as KEYTRUDA or MK-3475, is approved in the USA and several other countries to treat other types of diseases.” NCT02971956 ↗ “Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.” NCT03504163 ↗ “Pembrolizumab (MK-3475): will be administered at a dose of 200mg by IV infusion every 3 weeks starting from cycle 1, day 1.” NCT06498518 ↗ “MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.” NCT02014636 ↗ “Pembrolizumab (MK-3475), an anti-PD-1 antibody, had a good activity against melanoma and other types of cancers.” NCT03544099 ↗ “This is a study of pembrolizumab (MK-3475) for participants with relapsed/refractory classical Hodgkin Lymphoma” NCT02453594 ↗ “in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma” NCT04251117 ↗ “pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1)” NCT02855203 ↗ “The immunotherapy involved in this study is: * Pembrolizumab (MK-3475 or KEYTRUDA).” NCT03087019 ↗ “Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide” NCT03834493 ↗ “The immunotherapy involved in this study is: MK-3475 (pembrolizumab or KEYTRUDA).” NCT03085719 ↗ “Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days)” NCT03182894 ↗ “the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475)” NCT02759575 ↗ “Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.” NCT04358237 ↗ “Pembrolizumab, also known as MK-3475, at different dose levels” NCT03345134 ↗ “the research study drug, Pembrolizumab (also known as MK-3475)” NCT03901378 ↗ “pembrolizumab (pembro or MK-3475) with or without bevacizumab” NCT03813394 ↗ “Pembrolizumab (MK-3475) is a humanized monoclonal antibody.” NCT02852655 ↗ “intravenous (IV) pembrolizumab (also known as MK-3475)” NCT06045767 ↗ “Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)” NCT03163992 ↗ “Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)” NCT04892472 ↗ “Treatment with MK-3475 (pembrolizumab) 200 mg.” NCT05737199 ↗ “Immunotherapy: Pembrolizumab (MK-3475)” NCT04443348 ↗ “* Pembrolizumab (Keytruda®; MK-3475)” NCT04448886 ↗ “Other Name: MK-3475; Keytruda” NCT04753879 ↗ “Pembrolizumab (MK-3475)” NCT03881111 ↗ “Pembrolizumab (MK-3475)” NCT07302347 ↗ “pembrolizumab (MK-3475)” NCT02586207 ↗ “pembrolizumab (MK-3475)” NCT04130542 ↗ “Pembrolizumab (MK-3475)” NCT03111732 ↗ “MK-3475 (Pembrolizumab)” NCT04533451 ↗ “Pembrolizumab (MK3475)” NCT04118036 ↗ “Pembrolizumab (MK3475)” NCT03932409 ↗ “MK-3475(pembrolizumab)” NCT02844075 ↗ “KEYTRUDA, MK-3475” NCT02981524 ↗ “Drug: MK-3475” NCT03003468 ↗ “MK-3475” NCT02504372 ↗ “MK-3475” NCT02375672 ↗ “MK-3475” NCT03918499 ↗ |
| Known as | MK-3475, Keytruda | “MK-3475, Keytruda” NCT02287428 ↗ |
| Known as | MK-3475/pembrolizumab (KEYTRUDA) | “MK-3475/pembrolizumab (KEYTRUDA®)” NCT02560636 ↗ |
| Known as | MK-3745 | “The purpose of this study is to determine the feasibility and evaluate the safety of delivering chemoradiotherapy, the usual approach to non-small cell lung cancer, in...” NCT02987998 ↗ |
| Known as | P28GST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02281916 ↗ |
| Known as | PBZ | “This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC).” NCT03272334 ↗ |
| Known as | PD-1 inhibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05374252 ↗ |
| Known as | PD-1 mAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03732547 ↗ |
| Known as | PEM | “Here, we present phase I safety results from an open-label, phase I/II study of pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) triplet therapy in advanced, B-Raf...” PMID 34655839 ↗ Oct 20211“pembrolizumab (PEM)” NCT04657991 ↗ |
| Known as | Pembolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998771 ↗ |
| Known as | Pembro | “To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro)...” NCT03253068 ↗9“The purpose of this study is to determine the efficacy and safety of pembrolizumab (pembro, MK-3475) with or without chemotherapy versus chemotherapy alone” NCT02853305 ↗ “Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5.” NCT05222087 ↗ “Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings.” PMID 37369081 ↗ Jun 2023 “Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles” NCT03515837 ↗ “The phase Ib/II KEYMAKER-U03 substudy 03A (NCT04626479) investigated novel pembrolizumab (pembro)-based regimens in this setting.” PMID 41115468 ↗ Oct 2025 “pembrolizumab (pembro) will be administered via intravenous (IV) infusion” NCT03010176 ↗ “pembrolizumab (pembro or MK-3475) with or without bevacizumab” NCT03813394 ↗ “200 mg Pembrolizumab (pembro) on day 1 of each cycle” NCT07021989 ↗ “Pembrolizumab (PEMBRO) + Chemotherapy” NCT05502237 ↗ |
| Known as | Pembrolizumab (EU) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06311721 ↗ |
| Known as | Pembrolizumab (Keytruda) | “Pembrolizumab (Keytruda®)” NCT05508737 ↗3“Pembrolizumab (KEYTRUDA®)” NCT05277402 ↗ “pembrolizumab (KEYTRUDA),” NCT03009058 ↗ “Pembrolizumab (KEYTRUDA®)” NCT04648202 ↗ |
| Known as | Pembrolizumab (Keytruda, MSD China) | “Pembrolizumab (Keytruda, MSD China)” NCT03895970 ↗ |
| Known as | pembrolizumab (MK-3475) | “pembrolizumab (MK-3475)” NCT06125197 ↗ |
| Known as | Pembrolizumab (US) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06311721 ↗ |
| Known as | Pembrolizumab 25mg/mL (MK-3475) | “Pembrolizumab 25mg/mL (MK-3475)” NCT04219254 ↗ |
| Known as | Pembrolizumab and Chemotherapy drugs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04547504 ↗ |
| Known as | Pembrolizumab injection | “Pembrolizumab Injection [Keytruda]” NCT04550624 ↗1“Pembrolizumab injection” NCT05809336 ↗ |
| Known as | pembrolizumab(Merck & Co., Inc.) | “pembrolizumab(Merck & Co., Inc.)” NCT03736330 ↗ |
| Known as | Pembrolizumab/Vibostolimab coformulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02861573 ↗ |
| Known as | Pembroluzimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513324 ↗ |
| Known as | PY159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682431 ↗ |
| Known as | PY314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04691375 ↗ |
| Known as | RPH-075 | “The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and...” NCT06307093 ↗ |
| Known as | SCH 900475 | “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗4“MK-3475 (previously known as SCH 900475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the...” NCT02636010 ↗ “MK-3475 (previously known as SCH 900475) is a potent and highly-selective humanized mAb of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and...” NCT02129556 ↗ “A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung...” NCT03664024 ↗ “SCH 900475” NCT03918499 ↗ |
| Known as | Sindillimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05792995 ↗ |
| Known as | Triprilumab | “Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin” NCT04413734 ↗1“Triprilumab” NCT04413734 ↗ |
| Known as | Triprilumab Injection | “This study is to analyze the safety and efficacy of immunotherapy Triprilumab Injection combined with Gemcitabine Injection plus Cisplatin Injection in patients with advanced...” NCT04413734 ↗ |
| Action | Inhibit | “The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.” PMID 27092830 ↗ Apr 2016 |
| Modality | Vaccine | “new cancer vaccine” NCT00101166 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00928902 ↗ |
| Target | PDCD1 | “the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab” PMID 27138582 ↗ May 2016 |